Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Rhea-AI Summary
Gossamer Bio (NASDAQ:GOSS) has entered into an option agreement to acquire Respira Therapeutics, a Samsara BioCapital portfolio company. The deal centers around RT234, a first-in-class inhaled vardenafil powder being developed as an as-needed (PRN) treatment for pulmonary hypertension (PH).
As part of the agreement, Gossamer will issue 2.5 million shares upfront and an additional 1.5 million shares upon exercising the acquisition option. The deal includes success-based milestone payments and royalties on potential RT234 sales. During the two-year option period, Gossamer will fund CMC development activities for RT234.
Positive
- Development of first-in-class as-needed (PRN) therapy for pulmonary hypertension where no PRN options currently exist
- Gossamer to fund development activities during the option period
- Deal includes milestone payments and royalties on potential sales
- Leverages Gossamer's established late-stage PH product development platform
Negative
- Two-year option period creates uncertainty about final acquisition completion
- Share-based transaction structure may lead to dilution for existing Gossamer shareholders
News Market Reaction
On the day this news was published, GOSS declined 7.02%, reflecting a notable negative market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $51M from the company's valuation, bringing the market cap to $680M at that time.
Data tracked by StockTitan Argus on the day of publication.
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD -
Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH). RT234 is designed to rapidly improve PH patient function and symptoms, including for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). There are no approved PRN therapies for PAH or PH-ILD, and despite existing treatment options, the majority of PH patients continue to struggle with debilitating symptoms that disrupt daily life and limit their independence.
"We look forward to working closely with our colleagues at Gossamer, who share our commitment to people living with PH, to expeditiously develop RT234 and making this unique therapy broadly available to patients," stated John Kollins, Respira's Chief Executive Officer.
"We are excited to pair Respira's technology and expertise with Gossamer's established late-stage PH product development platform," said Michael Dybbs, member of the Respira Board of Directors and partner at Samsara BioCapital. "We are confident that this transaction favorably positions RT234 to advance into late-stage clinical development."
Pursuant to the option agreement, Gossamer is issuing 2.5 million shares of common stock in connection with the signing. Additionally, upon exercise of its acquisition option, Gossamer will issue an additional 1.5 million shares of common stock. In addition, the acquisition agreement provides for certain success-based clinical, regulatory, and commercial milestone payments and a royalty on potential net sales of RT234. During the option period, which is anticipated to continue for up to approximately two years, Gossamer will fund and Respira will undertake certain pre‑agreed development activities focused on CMC work necessary to position RT234 for successful subsequent clinical development.
Respira is being advised by Sidley Austin LLP,
About Respira Therapeutics and RT234
Respira Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary hypertension patients can self-administer as-needed (PRN) to provide rapid, on-demand relief of exertional symptoms, such as breathlessness and reduced ability to perform basic daily activities, on top of chronic background therapies. These symptoms are widely prevalent among PH patients and often highly debilitating and disruptive to patients' daily lives.
RT234 incorporates novel and proprietary dry-powder formulation and inhaler technologies, including Respira's Axial Oscillating Sphere Dry Powder Inhaler (AOS™-DPI), which maximize drug delivery to the deep lung. Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor approved in an oral dosage form for a non-PH indication. Although the PDE5 inhibitors sildenafil and tadalafil are FDA-approved in oral dosage forms for chronic treatment of PAH, on-demand administration of PDE5 inhibitors by inhalation in PH represents a novel treatment approach. Unlike existing PH treatments, RT234 is designed to provide rapid, on-demand relief of exertional symptoms and to be used on top of background therapies.
In two completed open‑label Phase 2 studies in which a total of 56 PAH patients were treated with RT234, RT234 demonstrated rapid and clinically meaningful improvements in both hemodynamic and functional measures. Hemodynamic benefits included reductions in pulmonary vascular resistance and favorable changes in mean pulmonary arterial pressure and cardiac output. Acute functional improvements were also observed, including reduced breathlessness and increased exercise capacity during cardiopulmonary exercise testing. To date, RT234 has demonstrated a favorable safety and tolerability profile.
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
About Samsara BioCapital
Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs. Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-seven years of industry experience and has an MD and a PhD in Immunology from Stanford University.
Contact:
Respira Therapeutics, Inc.
John Kollins
Chief Executive Officer
ir@respiratherapeutics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/respira-therapeutics-enters-into-agreement-with-gossamer-bio-gossamer-granting-gossamer-option-to-acquire-respira-from-samsara-biocapital-302567055.html
SOURCE Respira Therapeutics, Inc.
FAQ
What is the acquisition deal between Gossamer Bio and Respira Therapeutics?
What is RT234 and how is it different from existing treatments?
How long is the option period for Gossamer Bio's potential acquisition of Respira?
What are the financial terms of the Gossamer Bio (GOSS) and Respira deal?
What is the potential market impact of RT234 for pulmonary hypertension patients?
